S. H. Lim, Anti-CD20 monoclonal antibodies: historical and future perspectives, Haematologica, vol.95, issue.1, pp.135-143, 2010.
DOI : 10.3324/haematol.2008.001628

A. C. Chan and P. J. Carter, Therapeutic antibodies for autoimmunity and inflammation, Nature Reviews Immunology, vol.10, issue.5, pp.301-316, 2010.
DOI : 10.1038/nri2761

D. G. Maloney, Anti-CD20 Antibody Therapy for B-Cell Lymphomas, New England Journal of Medicine, vol.366, issue.21, 2008.
DOI : 10.1056/NEJMct1114348

M. J. Glennie, R. R. French, M. S. Cragg, and R. P. Taylor, Mechanisms of killing by anti-CD20 monoclonal antibodies, Molecular Immunology, vol.44, issue.16, pp.3823-3837, 2007.
DOI : 10.1016/j.molimm.2007.06.151

F. Montalvao, The mechanism of anti-CD20???mediated B cell depletion revealed by intravital imaging, Journal of Clinical Investigation, vol.123, issue.12, pp.5098-5103, 2013.
DOI : 10.1172/JCI70972DS1

URL : https://hal.archives-ouvertes.fr/pasteur-01410108

N. Gul, Macrophages eliminate circulating tumor cells after monoclonal antibody therapy, Journal of Clinical Investigation, vol.124, issue.2, pp.812-823, 2014.
DOI : 10.1172/JCI66776DS1

Q. Gong, Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy, The Journal of Immunology, vol.174, issue.2, pp.817-826, 2005.
DOI : 10.4049/jimmunol.174.2.817

P. Umana, J. Jean-mairet, R. Moudry, H. Amstutz, and J. Bailey, Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity, Nature biotechnology, vol.17, pp.176-180, 1999.

C. Ferrara, F. Stuart, P. Sondermann, P. Brunker, and P. Umana, The Carbohydrate at Fc??RIIIa Asn-162: AN ELEMENT REQUIRED FOR HIGH AFFINITY BINDING TO NON-FUCOSYLATED IgG GLYCOFORMS, Journal of Biological Chemistry, vol.281, issue.8, pp.5032-5036, 2006.
DOI : 10.1074/jbc.M510171200

R. Jefferis, Glycosylation as a strategy to improve antibody-based therapeutics, Nature Reviews Drug Discovery, vol.99, issue.3, pp.226-234, 2009.
DOI : 10.1038/nrd2804

S. Herter, Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity, The Journal of Immunology, vol.192, issue.5, pp.2252-2260, 2014.
DOI : 10.4049/jimmunol.1301249

N. Kamada and R. Y. Carne, ORTHOTOPIC LIVER TRANSPLANTATION IN THE RAT, Transplantation, vol.28, issue.1, pp.47-50, 1979.
DOI : 10.1097/00007890-197907000-00011

R. N. Germain, E. A. Robey, and M. D. Cahalan, A Decade of Imaging Cellular Motility and Interaction Dynamics in the Immune System, Science, vol.336, issue.6089, pp.1676-1681, 2012.
DOI : 10.1126/science.1221063

P. Bousso and H. D. Moreau, Functional immunoimaging: the revolution continues, Nature Reviews Immunology, vol.19, issue.12, pp.858-864, 2012.
DOI : 10.1038/nri3342

C. Ferrara, Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co-expression of heterologous ??1, 4-N-acetylglucosaminyltransferase III and Golgi ??-mannosidase II, Biotechnology and Bioengineering, vol.15, issue.5, pp.851-861, 2006.
DOI : 10.1002/bit.20777

J. Uchida, The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. The Journal of experimental medicine 199, pp.1659-1669, 2004.

S. A. Beers, Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection, Blood, vol.115, issue.25, pp.5191-5201, 2010.
DOI : 10.1182/blood-2010-01-263533

E. Mossner, Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity, Blood, vol.115, issue.22, pp.4393-4402, 2010.
DOI : 10.1182/blood-2009-06-225979

S. Herter, Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models, Molecular Cancer Therapeutics, vol.12, issue.10, pp.2031-2042, 2013.
DOI : 10.1158/1535-7163.MCT-12-1182

V. Goede, Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions, New England Journal of Medicine, vol.370, issue.12, pp.1101-1110, 2014.
DOI : 10.1056/NEJMoa1313984

T. R. Tipton, Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies, Blood, vol.125, issue.12, pp.1901-1909, 2015.
DOI : 10.1182/blood-2014-07-588376